Abstracts tagged "tobacco use and vasculitis"

Abstract Number: 1885 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s disease): A Multicenter Study of 224 Patients
Alexandre LE JONCOUR¹, Simon Soudet², Axelle Dupont³, Olivier Espitia⁴, Fabien Koskas⁵, Philippe Cluzel⁶, Pierre-Yves Hatron², Joseph Emmerich⁷, Patrice Cacoub¹, Matthieu Resche-Rigon³, Marc Lambert² and David Saadoun¹, ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier Pitié, Paris, France, ²Département de Médecine Interne et Immunologie Clinique, CHU Lille, F-59000 Lille, France, Centre National de Référence des Maladies Autoimmunes et Systémiques Rares (Sclérodermie), France, Lille, France, ³3Service de Biostatistique et Information médicale, Hôpital Saint-Louis, APHP, Paris, France, Paris, France, ⁴Département de Médecine interne, CHU de Nantes, France, Nantes, France, ⁵Service de chirurgie vasculaire, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France, ⁶Service d’Imagerie Cardiovasculaire, Institut de cardiologie, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France, ⁷Department of Vascular Medicine and Cardiology, University Hospital Hotel Dieu, University Paris-Descartes, Paris, France, Paris, France
Background/Purpose: Data regarding long term outcome of patients with thromboangiitis obliterans (TAO) are lacking and most series come from India and Japan. We assess long-term…
Abstract Number: 2964 • 2016 ACR/ARHP Annual Meeting
Thromboangiitis Obliterans (Buerger’s disease) : An Observational Study of 174 Patients
Alexandre LE JONCOUR¹, Simon Soudet², Hélène Maillard², Fabien Koskas³, Philippe Cluzel⁴, Eric Hachulla⁵, Pierre-Yves Hatron⁵, Patrice Cacoub¹, Marc Lambert² and David Saadoun¹, ¹Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ²Department of internal medecine, Hôpital Claude Huriez, CHRU Lille, France, Lille, France, ³Department of vascular surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁴Department of cardiovascular imagery, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié Salpétrière, 83 Boulevard de l'Hôpital, 75013, Paris, France., Paris, France, ⁵CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France
Background/Purpose: Buerger’s disease or thromboangiitis obliterans (TAO) is a nonatherosclerotic segmental inflammatory disease of small- and medium-sized arteries of the distal extremities. This disease mainly…
Abstract Number: 1763 • 2014 ACR/ARHP Annual Meeting
Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis
Lucas Benarous¹, Benjamin Terrier², Bertrand Dunogué³, Pascal Cohen⁴, Xavier Puéchal⁴, Claire Le Jeunne⁴, Luc Mouthon⁴ and Loïc Guillevin for the French Vasculitis Study Group⁴, ¹Cochin Hospital, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³Internal Medicine, Hôpital Cochin, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Occupational and non-occupational exposures may play a role in the occurrence of ANCA-associated vasculitides (AAV) and affect their initial clinical-biological phenotype. Among these potential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].